Barr Ellison Solicitors – commercial property
Advertisement: Bradfield Centre mid
Advertisement: RSM
ARM Innovation Hub
Advertisement Cambridge China Centre
Advertisement: Lynch Wood Park
Advertisement: Cambridge Network
Advertisement EY mid banner
RealVNC mid banner careers
Advertisement: Mogrify mid banner
Mid banner advertisement: BDO
RealVNC mid-banner general
12 December, 2018 - 11:43 By Kate Sweeney

Edmunds elevated to key role at Mission Therapeutics

Mission Therapeutics, a leading Cambridge drug discovery and development company, has appointed Dr Nick Edmunds as vice-president, head of DUB Discovery.

The company is focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs).

Dr Edmunds has over 15 years’ pharmaceutical industry experience and a track record of delivery across small molecule preclinical drug discovery and early clinical development. 

He joined Mission as a senior director in September from AstraZeneca, where he had previously held a number of senior roles in drug safety and metabolism, including senior director, head of new modalities and director of safety pharmacology.

Prior to that, he was a Research Fellow at Pfizer Global Research and Development, Groton, USA and the Cardiovascular Discipline Leader in Global Safety Pharmacology at Pfizer Global Research and Development, Sandwich, UK.  

Dr Anker Lundemose, Mission’s CEO, said: “I am very pleased to welcome Nick to Mission Therapeutics’ Management team, especially at this exciting time following the announcement of a major collaboration with AbbVie. 

“Nick has the right skills, experience, enthusiasm and mindset to provide superb leadership to our research team and to advance our discovery DUB programmes.”

Newsletter Subscription

Stay informed of the latest news and features